Table 2 Baseline characteristics of the pooled patients
Normal eGFR (eGFR ≥ 90 mL/min/1.73m2) | Mildly reduced eGFR (60 ≤ eGFR < 90 mL/min/1.73m2) | |||
|---|---|---|---|---|
Enavogliflozin 0.3 mg (n = 106) | Dapagliflozin 10 mg (n = 117) | Enavogliflozin 0.3 mg (n = 129) | Dapagliflozin 10 mg (n = 118) | |
Male, n (%) | 49 (46.23) | 60 (51.28) | 83 (64.34) | 62 (52.54) |
Age, years | 56.13 (11.23) | 56.83 (10.79) | 60.49 (9.72) | 62.36 (8.61) |
Weight, kg | 69.52 (11.68) | 69.70 (12.60) | 70.95 (11.65) a | 67.82 (10.65) a |
BMI, kg/m2 | 26.29 (3.88) | 26.26 (3.34) | 26.20 (3.22) | 25.48 (3.05) |
Duration of diabetes, years | 8.39 (6.27) | 7.48 (5.15) | 10.66 (6.81) | 10.38 (5.54) |
OHA history, n (%) | ||||
Metformin alone | 21 (19.81) | 34 (29.06) | 38 (29.46) | 26 (22.03) |
Add-on therapy to metformin | 85 (80.19) | 83 (70.94) | 91 (70.54) | 92 (77.97) |
HbA1c, % | 7.93 (0.82) | 7.90 (0.81) | 7.90 (0.79) | 7.94 (0.78) |
HbA1c, mmol/mol | 63.16 (8.99) | 62.88 (8.81) | 62.87 (8.64) | 63.26 (8.55) |
HbA1c ≥ 8% (64 mmol/mol), n (%) | 38 (35.85) | 38 (32.48) | 43 (33.33) | 44 (37.29) |
FPG, mg/dL | 165.96 (35.87) | 161.27 (32.22) | 160.40 (30.52) | 159.71 (32.34) |
eGFR, mL/min/1.73m2 | 105.18 (13.23) | 106.80 (13.47) | 76.71 (8.06) | 77.97 (7.73) |
SBP, mmHg† | 126.67 (10.88) | 125.82 (11.92) | 129.37 (14.37) b | 125.68 (13.57) b |
DBP, mmHg† | 76.49 (8.81) | 75.61 (8.72) | 76.77 (10.05) c | 74.11 (10.57) c |